



Supplementary Figure 1




Supplementary Figure 2



Supplementary Figure 3


Patient 1

Stage IV-M1a melanoma
Refractory to nivolumab, ipilimumab/nivolumab, topical imiquimod
NGS: MEK1




Patient 2

Stage IV-M1c melanoma
Refractory to nivolumab, ipilimumab/nivolumab, TLDD, TMZ
NGS: SMARCA4, TP53, MSH6




Patient 3

Stage IV-M1a melanoma
Refractory to pembrolizumab, ipilimumab/nivolumab
NGS: SMARCA4, SMARCB1




Patient 4

Stage IV-M1a melanoma
Refractory to pembrolizumab, isolated limb perfusion, monotherapy ipilimumab
NGS: NRAS^{Q61}




Patient 8

Stage IV-M1a melanoma
Refractory to nivolumab, ipilimumab/nivolumab, topical imiquimod
NGS: MEK1




Patient 5

Stage IV-M1c melanoma
Refractory to nivolumab, monotherapy ipilimumab
NGS: NRAS^{Q61}




Patient 6

Stage IV-M1a melanoma
Refractory to nivolumab, ipilimumab/nivolumab
NGS: NRAS^{Q61}




Supplementary Figure 4




Supplementary Figure 5


A



B



C



A Supplementary Figure 6

B

